Pradaxa Bleeding Events Prompt FDA To Revise Generic Bioequivalence Criteria

Revamped ANDA instructions – among new and revised draft guidance for 58 products announced by FDA – 'account for the fact that dabigatran exhibits large within-subject variability with respect to blood levels.'